Global Cancer Technology (GCT) CEO and founder, John Clark, was recently interviewed by Proactive Investors Online regarding GCT's atypically fast SEC approval for a Reg A+ shares filing. The $9 million fundraising round ongoing now is focused on applying a novel drug delivery treatment and brain cancer inhibitor to advance efforts in managing glioblastoma. Glioblastoma, also known as "brain cancer," is notoriously challenging to treat and the majority of those diagnosed die 18-20 months later. For patients and their loved ones, this is a heart-breaking diagnosis.
In his Proactive Investors interview, John also highlighted that, a portion of GCT's net proceeds will be used to develop and commercialize its recently licensed technology to treat the coronavirus using nanoparticles, UV light and chest x-rays. See the rest of the interview at the links below.
- Proactive Investors Online (May 26, 2021 reached more than 260,000 site visitors): https://www.
proactiveinvestors.com/ companies/news/950643/global- cancer-technology-to-raise-9m- through-a-reg-a-offering-to- fund-potential-covid- treatment-950643.html
- Proactive Investors YouTube (May 26, 2021): https://www.youtube.com/watch?
Additional Coverage can be found here: